About Us

Creating a Better World
with Digital Therapeutics

Hippo T&C is a healthcare company developing digital therapeutic devices using VR and AI technologies. We strive to solve mental health issues such as depression and ADHD scientifically and effectively.

Vision

Growing Together with Digital Therapeutics

We dream of a world where everyone is free from mental health issues and can live a better life with the help of technology.

Mission

Evidence-Based Innovative Digital Treatment

We develop clinically validated digital therapeutic devices and provide mental health solutions that are accessible to everyone.

What We Stand For

Core Values

🎯

Scientific Approach

All solutions are developed based on clinical research and scientific evidence.

🤝

Patient-Centered

We prioritize patient treatment experience and quality of life improvement.

💡

Pursuing Innovation

We present new treatment paradigms using cutting-edge technologies like VR and AI.

🔒

Trust and Safety

We build trust through strict quality control and personal data protection.

Our Journey

History

Explore the milestones of Hippo T&C.

2026
January

Establishes U.S. Subsidiary (Hippo T&C USA, LLC)

6310 Hillside Court, Suite 160, Columbia, Maryland 21046 USA

January

BlueKare Designated as Innovative Medical Device

MFDS (Ministry of Food and Drug Safety) General No. 122

2025
November

2025 Korea AI Innovation Award

Grand Prize in AI Healthcare Category

June

BlueKare Approved as Korea's First Digital Therapeutics for Depression

Ministry of Food and Drug Safety, License No. D제허25-1호

May

Issuance of Manufacturing License for Digital Medical Devices

Ministry of Food and Drug Safety, PUPH-T5MN-NKXW-M0RL

April

Certificate of Good Manufacturing Practice (GMP) for Medical Device Manufacturing and Quality Management

March

Graduated from the SKKU Business Incubation Center and Relocated Headquarters to Pangyo

502, A-dong, Pangyo Digital Center, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

2024
December

AttnKare-D, clinical trial termination at Mount Sinai Hospital in New York, USA

Jeffrey Newcorn Professor Research Team

November

Official Launch of Digital Health Solutions CogMo and WithBuddy

June

Selected as a 2024 Global ICT Future Unicorn

hosted by the Ministry of Science and ICT

June

Selected for the AI-based digital transformation project for public healthcare institutions

hosted by NIPA

June

Selected for Post TIPS hosted by the Ministry of SMEs and Startups

April

Initiation of investigator-initiated clinical trials for AttnKare-D at Mount Sinai Hospital in the United States

January

Poster presentation and booth exhibition of AttnKare-D and AttnKare-T at APSARD 2024

2023
November

AttnKare-D, approved for confirmatory clinical trial by Ministry of Food and Drug Safety

November

AttnKare-D, clinical trial termination at the University of Nebraska Medical Center (UNMC), USA

October

AttnKare-D Research AACAP2023 Poster Exhibition

ADHD Symptom Assessment Using Artificial Intelligence to Parse Virtual Reality Task Performance

July

AttnKare-T, researcher clinical trial begins

Sungkyunkwan University School of Medicine, Korea Brain Research Institute

July

BlueKare-T, public medical project researcher clinical trial begins

June

Participation in public medical projects

June

AttnKare-D researcher clinical trial begins at the University of Nebraska, USA

June

BlueKare-T approved for confirmatory clinical trial by Ministry of Food and Drug Safety

Clinical trials at three institutions: Seoul Samsung Hospital, Seoul Asan Medical Center, and Seoul National University Bundang Hospital

May

Received order for NIPA global market entry project

May

BlueKare-T, SW Validation

KTL SW Validation & Cyber Security & Performance Evaluation, judged 'suitable' in 3 categories

May

AttnKare-D, SW Validation

KTL SW Validation & Cyber Security judged 'suitable' in 2 categories

April

Hippo T&C affiliated research institute selected as a specialized military service exception company

March

Hippo T&C Showcase held

January

AttnKare-D, AttnKare-D, BlueKare-T CES exhibition

January

AttnKare-D, approved for exploratory clinical trial by Ministry of Food and Drug Safety

Clinical trials at two institutions, Seoul Samsung Hospital and Changwon Samsung Hospital

January

AttnKare-D poster presentation and exhibition participation at APSARD

2022
December

Received a commendation from the Minister of Science and ICT

December

Received a commendation from Gyeonggi Province Governor

Contribute to local economic development by revitalizing entrepreneurship

December

Selected for TIPS follow-up startup commercialization and overseas marketing project hosted by the Ministry of SMEs and Startups

November

Recognized as a K-GMP software (Software as a Medical Device) item

November

Received a commendation from Dong-A Ilbo President

September

AttnKare-D, acquired medical device SW validation

July

BlueKare-T, emotional disorder treatment software medical device grade 2 designated by the Ministry of Food and Drug Safety

June

AttnKare-D, cognitive assessment software medical device grade 2 designated by the Ministry of Food and Drug Safety

January

CES 2022 Innovation Award in Virtual-Augmented Reality/Digital Health-Wellness Category

January

Hippo T&C products displayed at CES 2022

AttnKare-D, AttnKare-T, BlueKare-T

2021
December

Attracting pre-series investment

September

AttnKare experience center opened in Woongjin Playcity, Bucheon

July

Received order to develop digital treatment for depression in the Corona Blue Era

Hosted by the Ministry of Trade, Industry and Energy

2020
November

Selected for TIPS (Tech Incubator Program for Startups) by the Ministry of SMEs and Startups

ADHD diagnosis and treatment development project

November

Acquisition of U-Tech Valley Certification of Kibo(KOREA TECHNOLOGY FINANCE CORPORATION)

October

Acquisition of Venture Business Certification

July

Establishment of Research Institute

April

Founding of Hippo T&C, Inc.

CEO Message

Message from the CEO

Tai-Myoung Chung

Tai-Myoung Chung

CEO / Founder

Hippo T&C was founded on the belief that "Hippocratic spirit can be realized through technology to care for people." Witnessing those suffering from mental health challenges firsthand, I became convinced that technology can serve as a true instrument of healing.

Digital therapeutics represent a new treatment paradigm — accessible to everyone, free from the side effects of medication. We are developing clinically validated solutions for ADHD, depression, and other mental health conditions, making a real difference in each patient's daily life.

Hippo T&C will continue to open up the future of digital healthcare through the convergence of technology and medicine. We appreciate your warm support and interest.

Career Highlights

  • Professor & Dean, College of Software, Sungkyunkwan University
  • President, Korean Society of Medical Informatics & Korea Information Processing Society
  • ICT Advisor, Republic of Rwanda
  • Vice-Chair, OECD Privacy Protection Division
  • Member, Presidential Advisory Committee on e-Government
  • Recipient, Order of Service Merit (Hong-jo), Republic of Korea
  • Researcher, BBN Labs., USA
  • Ph.D. in Computer Science, Purdue University, USA